These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 11599485

  • 21. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [Abstract] [Full Text] [Related]

  • 22. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
    Ueland T, Bollerslev J, Mosekilde L.
    Ugeskr Laeger; 2002 Jul 01; 164(27):3526-30. PubMed ID: 12116680
    [Abstract] [Full Text] [Related]

  • 23. The OPG/RANKL/RANK system in metabolic bone diseases.
    Hofbauer LC, Kühne CA, Viereck V.
    J Musculoskelet Neuronal Interact; 2004 Sep 01; 4(3):268-75. PubMed ID: 15615494
    [Abstract] [Full Text] [Related]

  • 24. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 01; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 25. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul 01; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 26. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT.
    J Rheumatol; 2005 Apr 01; 32(4):713-20. PubMed ID: 15801030
    [Abstract] [Full Text] [Related]

  • 27. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T.
    Anat Rec; 2002 Oct 01; 268(2):137-46. PubMed ID: 12221720
    [Abstract] [Full Text] [Related]

  • 28. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.
    J Periodontal Res; 2006 Aug 01; 41(4):288-96. PubMed ID: 16827722
    [Abstract] [Full Text] [Related]

  • 29. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 01; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 30. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE.
    J Cell Biochem; 2002 Jul 01; 86(4):642-50. PubMed ID: 12210731
    [Abstract] [Full Text] [Related]

  • 31. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors.
    Gallant MA, Samadfam R, Hackett JA, Antoniou J, Parent JL, de Brum-Fernandes AJ.
    J Bone Miner Res; 2005 Apr 01; 20(4):672-81. PubMed ID: 15765187
    [Abstract] [Full Text] [Related]

  • 32. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K, Hirukawa K, Nakamura H, Togari A.
    Neurosci Lett; 2005 Apr 29; 379(1):47-51. PubMed ID: 15814197
    [Abstract] [Full Text] [Related]

  • 33. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug 29; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 34. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb 29; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 35. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S, Kiyokawa A, Nagayama Y.
    Clin Calcium; 2005 Jan 29; 15(1):35-42. PubMed ID: 15632471
    [Abstract] [Full Text] [Related]

  • 36. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF, Lie A, Ransjö M.
    J Cell Biochem; 2006 Oct 01; 99(2):528-37. PubMed ID: 16639710
    [Abstract] [Full Text] [Related]

  • 37. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin.
    Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J.
    J Bone Miner Res; 2006 Feb 01; 21(2):228-36. PubMed ID: 16418778
    [Abstract] [Full Text] [Related]

  • 38. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
    Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D.
    J Bone Miner Res; 2006 Mar 01; 21(3):438-45. PubMed ID: 16491292
    [Abstract] [Full Text] [Related]

  • 39. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Endocrinology; 2005 Apr 01; 146(4):1991-8. PubMed ID: 15618359
    [Abstract] [Full Text] [Related]

  • 40. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ, Ji ZL, Chen SM.
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov 01; 19(6):655-60. PubMed ID: 15971575
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.